Theriva Biologics Inc
AMEX:TOVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TOVX's latest stock split occurred on Aug 26, 2024
The company executed a 1-for-25 stock split, meaning that for every 25 shares held, investors received 1 new share.
Before the split, TOVX traded at 0.14 per share. Afterward, the share price was about 3.3.
The adjusted shares began trading on Aug 26, 2024. This was TOVX's 5th stock split, following the previous one in Jul 25, 2022.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 28, 2026
|
|
Kura Sushi Inc
TSE:2695
|
2-for-1
x2
|
3565 1782.5 JPY | 1745 1745 JPY |
|
Apr 28, 2026
|
|
Sanki Engineering Co Ltd
TSE:1961
|
3-for-1
x3
|
7020 2340 JPY | 2413 2413 JPY |
|
Apr 28, 2026
|
|
Hyterra Ltd
ASX:HYT
|
65-for-64
x1.015625
|
0.015 0.0148 AUD | 0.015 0.015 AUD |
|
Apr 28, 2026
|
|
Fit Corp
TSE:1436
|
3-for-1
x3
|
4065 1340 JPY | 1269 1269 JPY |
|
Apr 28, 2026
|
|
Visual Processing Japan Co Ltd
TSE:334A
|
2-for-1
x2
|
1844 922 JPY | 965 965 JPY |
2695
1961
HYT
1436
334A
Theriva Biologics Inc
Glance View
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 21 full-time employees. The firm is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patients immune system. The Company’s lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
